All Title Author
Keywords Abstract

PLOS Medicine  2011 

Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis

DOI: 10.1371/journal.pmed.1001063

Full-Text   Cite this paper   Add to My Lib



[1]  Pai M, Minion J, Steingart K, Ramsay A (2010) New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16: 271–284.
[2]  World Health Organization (2010) Framework for implementing new tuberculosis diagnostics. Geneva: WHO. Available: Accessed 24 June 2011.
[3]  Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005–1015.
[4]  Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495–1505.
[5]  World Health Organization (2010) WHO endorses new rapid tuberculosis test. Available: Accessed 13 March 2011.
[6]  Foundation for Innovative New Diagnostics (2010) FIND Negotiated Priced for Xpert MTB/RIF and Country List. Available: Accessed 7 March 2011.
[7]  Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC (1996) The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 276: 1172–1177.
[8]  Dowdy DW, Louren?o MC, Cavalcante SC, Saraceni V, King B, et al. (2008) Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS ONE 3: e4057.
[9]  Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, et al. (2008) Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 47: 487–495.
[10]  Dowdy DW, O'Brien MA, Bishai D (2008) Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1021–1029.
[11]  Commission on Macroeconomics and Health (2001) Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization.
[12]  Scherer LC, Sperhacke RD, Ruffino-Netto A, Rossetti ML, Vater C, et al. (2009) Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis. BMC Infect Dis 9: 216.
[13]  Basinga P, Moreira J, Bisoffi Z, Bisig B, Van den Ende J (2007) Why are clinicians reluctant to treat smear-negative tuberculosis? An inquiry about treatment thresholds in Rwanda. Med Decis Making 27: 53–60.
[14]  Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, et al. (2007) A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11: 1–196.
[15]  Ling DI, Flores LL, Riley LW, Pai M (2008) Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 3: e1536.
[16]  Pauker SG, Kassirer JP (1980) The threshold approach to clinical decision making. N Engl J Med 302: 1109–1117.
[17]  Davis JL, Katamba A, Vasquez J, Crawford E, SSerwanga A, et al. (2011) Evaluating Tuberculosis Case Detection via Real-time Monitoring of Tuberculosis Diagnostic Services. Am J Respir Crit Care Med. In press.
[18]  Baltussen R, Floyd K, Dye C (2005) Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331: 1364.
[19]  Central Intelligence Agency (2010) CIA world factbook. CIA: Washington (D.C.). Available: Accessed 25 March 2011.
[20]  Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, et al. (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336: 1106–1110.
[21]  Mann G, Squire SB, Bissell K, Eliseev P, Du Toit E, et al. (2010) Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 14: 1518–1524.
[22]  Moreira J, Bisig B, Muwawenimana P, Basinga P, Bisoffi Z, et al. (2009) Weighing harm in therapeutic decisions of smear-negative pulmonary tuberculosis. Med Decis Making 29: 380–390.
[23]  Moulton LH, Golub JE, Durovni B, Cavalcante SC, Pacheco AG, et al. (2007) Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 4: 190–199.
[24]  Frieden TR (2009) Lessons from tuberculosis control for public health. Int J Tuberc Lung Dis 13: 421–428.
[25]  Bishai D (2009) Cost-effectiveness of screening for tuberculosis. Available: Accessed 14 March 2011.


comments powered by Disqus